Navigation Links
Nventa Appoints John Varian to Board of Directors
Date:5/7/2008

- New Member Complements Board With Significant Financial and Operational

Expertise -

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of John Varian to the company's board of directors. Mr. Varian currently serves as the chief operating officer and chief financial officer of Aryx Therapeutics, a pharmaceutical company focused on the discovery and development of oral therapeutics for chronic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are very pleased to welcome John to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His extensive experience in helping companies establish strategic direction, raise venture and public capital, and negotiate successful alliances and acquisitions should be extremely beneficial to Nventa as it grows internally and continues its path to commercializing its first product."

Prior to joining Aryx Therapeutics, Mr. Varian was chief financial officer of Genset S.A., where he was a key member of the team negotiating the company's sale to Serono S.A. in 2002. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation's chief financial officer from June 1997 until October 1998. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference.

"I am proud to join the board at Nventa Biopharmaceuticals, a truly innovative company that is working to bring much needed therapeutic options to patients affected by HPV-related diseases," stated Mr.
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventas CEO to present at two upcoming investor conferences
6. Nventa announces publication of HspE7 data
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Kendle Appoints Patricia Williams Vice President, Commercial Operations
9. Biomoda Appoints Three Business Leaders to Board of Directors
10. Shengtai Pharmaceutical, Inc. Appoints New CFO
11. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... and Harvard Deploys Isilon Clustered Storage to ... Growth, SEATTLE, Sept. 15 Isilon(R) Systems ... that the Broad,Institute of MIT and Harvard, one ... has deployed Isilon IQ clustered storage to,streamline mission-critical ...
... Inc.,(NYSE: BMR ) today announced that its board of ... share of common stock. The,dividend is equivalent to an annualized ... that its board of directors has declared a,dividend of $0.46094 ... Stock for the period from July 16, 2008 through,October 15, ...
... Sept. 12 Fougera, a division of Nycomed,US ... Clotrimazole Cream USP,1%. The generic formulation compares to ... three sizes: 15g tubes (NDC # 0168-0133-15), 30g ... 0168-0133-46)., "The approval of Clotrimazole Cream is ...
Cached Biology Technology:Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 2Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 3BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends 2
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... some other type of transcendent entity answer prayer? , ... study published in the March journal Research on Social ... of social work in the College of Human Services ... 17 major studies on the effects of intercessory prayer ...
... Worldwide, billions of people lack access to a reliable ... To address the problem, the United Nations established the ... of people without sustainable access to safe drinking water ... launched in 2000 as part of the U.N. Millennium ...
... When a virus infects a person, it triggers a series ... life or death consequences. , Usually, the result is ... virus and the infected person’s recovery. But in the case ... Marburg and Lassa fever viruses, as well as the influenza ...
Cached Biology News:Does God answer prayer? ASU research says 'yes' 2Failure to meet United Nations sanitation target could affect millions of the world's poorest 2Failure to meet United Nations sanitation target could affect millions of the world's poorest 3New study may show how to forestall a fatal, virus-caused immune-system meltdown 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 3
...
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Biology Products: